Activation Only When Both Markers Are Present: VERAXA Explores Dual Recognition in Cancer Treatment
Getting antibodies to recognize cancer cells is not enough to prevent unintended damage. VERAXA splits treatment into two complementary components to test a dual-marker activation strategy in cell and mouse studies; whether this can provide the safety margin needed in humans still awaits clinical validation.